Eisai has slashed 2027 sales projections for its Biogen-partnered Alzheimer’s treatment Leqembi by roughly half.
The Japanese drugmaker said it expects annual Leqembi sales to reach $1.7 billion to $1.9 billion in fiscal 2027 ...
↧
